Condition

B-cell Lymphoma clinical trials and research

• 40Clinical trials
• 33NIH research projects
• 21Countries

Newest B-cell Lymphoma clinical trials

All recruiting trials (40)

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Toxin exposure and immune factors in B-cell non-Hodgkin lymphoma

  This study tests how toxin exposure, genetics, and immune issues relate to B-cell non-Hodgkin lymphoma in active-duty service members and other Military Health System beneficiaries.

  Recruiting Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland and 2 other locations · NCT07652580

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• Bendamustine vs standard lymphodepletion before CAR-T in LBCL

  This trial tests whether bendamustine can replace the standard bendamustine-free lymphodepletion before CAR-T therapy in adults with large B-cell lymphoma who have had prior treatment.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Aarau and 8 other locations · NCT07593482

• CD19-targeted CAR-T cells that make p40 for relapsed or refractory CD19-positive blood cancers

  This trial will try a patient's own CD19-directed CAR-T cells engineered to produce p40 to see if they work better and last longer in adults with relapsed or refractory CD19-positive blood cancers.

  Recruiting Phase 1/2 Shenzhen University General Hospital · Shenzhen, Other (Non U.s.) · NCT07584889

• NX-5948 plus other medicines for B-cell cancers

  This trial tests NX-5948 in combination with venetoclax, with or without anti-CD20 antibodies, for adults with CLL/SLL or B-cell lymphoma that has returned or worsened or is newly diagnosed but needing treatment.

  Recruiting at 5 sites Phase 1/2 Nurix Therapeutics, Inc. · Aurora, Colorado and 8 other locations · NCT07520006

• NX-5948 vs Pirtobrutinib in R/R CLL/SLL

  This study tests NX-5948 against pirtobrutinib in people with relapsed or refractory CLL/SLL who have previously tried a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Nurix Therapeutics, Inc. · Macon, Georgia and 5 other locations · NCT07516093

• BAFF‑R CAR‑T treatment for adults with CD19‑negative relapsed or refractory B‑cell lymphoma

  This trial will see if BAFF‑R CAR‑T cells are safe and tolerable for adults whose B‑cell lymphoma has returned or not responded and is CD19‑negative.

  Recruiting Phase 1 Jiangsu Topcel-KH Pharmaceutical Co., Ltd. · Suzhou · NCT07369492

• Zanubrutinib plus rituximab for secondary HLH linked to B‑cell lymphoma

  This test tries zanubrutinib together with rituximab (plus short steroids and ruxolitinib, with emapalumab if needed) to treat people who have secondary HLH caused by B‑cell lymphoma.

  Recruiting Phase 4 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07270835

• Anti-CD19 gene therapy for B-cell lymphoma

  This trial will try an Anti-CD19 gene injection in adults with relapsed or refractory B-cell lymphoma to see if it is safe and can shrink tumors.

  Recruiting Anhui Provincial Hospital · Hefei, Anhui · NCT07211048

• New therapy dose test for people with prior B-cell cancers

  This early-phase study tests different doses of LY4152199 to see if it is safe and effective for people who have already been treated for certain B-cell lymphomas.

  Recruiting at 25 sites Phase 1 Eli Lilly and Company · Duarte, California and 50 other locations · NCT07101328

• U01 (ssCART-19) treatment for relapsed or refractory B‑cell lymphoma

  This treatment will try CD19-targeted CAR‑T cells called ssCART‑19 (with an IL‑6 silencing element) in people aged 2–75 whose B‑cell lymphoma has relapsed or not responded to prior therapy.

  Recruiting Phase 1 Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · Shanghai · NCT07093073

• BCOR and ZC3H12 knockout CD19 CAR-T therapy for relapsed/refractory B‑cell lymphoma

  This will try an autologous CD19 CAR‑T treatment with two genes (BCOR and ZC3H12) turned off to see if it works better for adults whose B‑cell lymphoma has returned or not responded to prior treatments.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07009002

• Evaluating a new cell therapy for B-Cell Lymphoma

  This study is testing a new cell therapy for people with hard-to-treat B-cell lymphoma to see if it is safe and effective at reducing side effects compared to traditional treatments.

  Recruiting Phase 1/2 Shanghai Tongji Hospital, Tongji University School of Medicine · Shanghai, Shanghai Municipality · NCT06987916

• Allogeneic CD19/BCMA CAR-T for relapsed or refractory B-cell and plasma cell cancers

  This study will test whether an off-the-shelf CAR-T product (RN1101) that targets CD19 and BCMA can help people with relapsed or refractory B-cell lymphomas and multiple myeloma.

  Recruiting Early Phase 1 Affiliated Hospital of Jiangsu University · Zhenjiang, Jiangsu · NCT06976437

• Evaluating XS-04 for patients with relapsed or refractory blood cancers

  This study is testing a new tablet called XS-04 to see if it is safe and how well it works for people with certain types of blood cancers that have come back or didn’t respond to other treatments.

  Recruiting at 2 sites Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Beijing and 3 other locations · NCT06820268

• Using Fourth-Generation CAR-T to treat blood cancers

  This study is testing a new type of CAR-T therapy to see if it can safely help people with blood cancers like Multiple Myeloma and B-cell Lymphoma.

  Recruiting Phase 1 The Third Affiliated Hospital of Southern Medical University · Guangzhou, Guangdong · NCT06758713

• Comparing sonrotoclax plus zanubrutinib to placebo plus zanubrutinib for relapsed mantle cell lymphoma

  This study is testing if adding sonrotoclax to zanubrutinib can help adults with relapsed mantle cell lymphoma feel better compared to just taking zanubrutinib with a placebo.

  Recruiting at 95 sites Phase 3 BeOne Medicines · Birmingham, Alabama and 144 other locations · NCT06742996

• Investigating a new cancer treatment for relapsed or refractory B-cell malignancies

  This study is testing a new cancer drug called BGB-16673 combined with other treatments to see if it can help people with tough-to-treat B-cell cancers feel better.

  Recruiting at 49 sites Phase 1/2 BeOne Medicines · Phoenix, Arizona and 48 other locations · NCT06634589

• Evaluating TQB3702 tablets with immunochemotherapy for B-cell lymphoma treatment

  This study is testing if TQB3702 tablets can work better with immunochemotherapy to help people with relapsed or hard-to-treat B-cell lymphoma.

  Recruiting Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 29 other locations · NCT06566586

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Early palliative care for patients with multiple myeloma and aggressive lymphoma

  This study is testing if early palliative care can improve the quality of life and comfort for people with multiple myeloma and aggressive lymphoma while they receive their usual cancer treatment.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT06485076

• Combination treatment of pembrolizumab and ATRA for relapsed Hodgkin and Non-Hodgkin lymphoma

  This study is testing if a combination of two treatments, pembrolizumab and ATRA, can help adults with relapsed Hodgkin and Non-Hodgkin lymphoma feel better and improve their health.

  Recruiting at 2 sites Phase 2 Indiana University · Indianapolis, Indiana and 1 other locations · NCT06484920

• Combining rituximab and zanubrutinib for treating indolent B-cell lymphomas

  This study is testing if combining two medications, rituximab and zanubrutinib, can help people with untreated indolent B-cell lymphomas feel better and improve their treatment outcomes.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06350318

• Combining axicabtagene ciloleucel and glofitamab for treating relapsed large B cell lymphoma

  This study is testing if combining two treatments, axicabtagene ciloleucel and glofitamab, can help people with relapsed large B cell lymphoma feel better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06213311

• CLIC-2201 treatment for relapsed B cell cancers

  This study is testing a new CAR-T cell therapy called CLIC-2201 to see if it can help people with relapsed B cell cancers feel better and improve their treatment outcomes.

  Recruiting at 7 sites Phase 1 British Columbia Cancer Agency · Calgary, Alberta and 6 other locations · NCT06208735

• Treatment for relapsed B-cell lymphoma using CAR-T cells

  This study is testing a new CAR-T cell therapy to see if it can help people with relapsed B-cell lymphoma feel better and improve their treatment outcomes.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Beijing, Beijing Municipality · NCT06180174

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Bispecific CAR-T cell therapy for relapsed B-cell cancers

  This study is testing a new type of CAR-T cell therapy that targets two cancer markers to see if it helps people with relapsed B-cell cancers feel better and have better outcomes.

  Recruiting Phase 2 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT06081478

• CAR20(NAP)-T therapy for B-cell lymphoma

  This study is testing a new treatment that uses modified immune cells to help people with B-cell lymphoma fight their cancer better, especially for those who haven't had success with other treatments.

  Recruiting at 2 sites Phase 1/2 Uppsala University · Stockholm and 1 other locations · NCT06002659

• Evaluating CTX112 for B-cell malignancies

  This study is testing a new type of CAR T cell therapy called CTX112 to see if it can safely help people with tough-to-treat B-cell cancers.

  Recruiting at 7 sites Phase 1/2 CRISPR Therapeutics · Westwood, Kansas and 6 other locations · NCT05643742

• Combination treatment for relapsed B-cell lymphoma

  This study is testing a new combination of treatments for people with relapsed B-cell lymphoma to see if it helps them respond better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05615636

• New CAR T-cell therapy for children and young adults with certain blood cancers

  This study is testing a new CAR T-cell therapy that uses modified cells from children's and young adults' own blood to see if it can help treat certain tough-to-treat blood cancers.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05442515

• IKS03 treatment for advanced B cell non-Hodgkin lymphomas

  This study is testing a new treatment called IKS03 for people with advanced B cell non-Hodgkin lymphoma to see how safe and effective it is.

  Recruiting at 12 sites Phase 1 Iksuda Therapeutics Ltd. · Baltimore, Maryland and 12 other locations · NCT05365659

• Local production of CAR T-cells for treating B-Cell cancers

  This study is testing whether making CAR T-cells locally can help patients with B-Cell lymphoma and leukemia have a safe and effective treatment.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT05281809

• Using engineered immune cells with chemotherapy to treat blood cancers

  This study is testing if using special immune cells along with chemotherapy can help people with tough-to-treat blood cancers like B-cell lymphoma and leukemia feel better.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05092451

• Testing LP-168 for patients with B-cell lymphoma that hasn't responded to previous treatments

  This study is testing a new oral medication called LP-168 to see if it can help patients with B-cell lymphoma who haven't had success with other treatments.

  Recruiting at 3 sites Phase 1 Guangzhou Lupeng Pharmaceutical Company LTD. · Beijing, Beijing Municipality and 2 other locations · NCT04993690

• First-line treatment for follicular and marginal zone lymphoma using mosunetuzumab and lenalidomide

  This study is testing if a new combination of treatments can help adults with untreated follicular or marginal zone lymphoma feel better and improve their response to therapy.

  Recruiting at 2 sites Phase 2 Brown University · New Haven, Connecticut and 2 other locations · NCT04792502

• Using stem cell transplant and Polatuzumab Vedotin for treating B-cell lymphomas

  This study is testing if a stem cell transplant followed by a new drug called Polatuzumab Vedotin can help people with different types of B-cell lymphomas feel better.

  Recruiting Phase 1/2 New York Medical College · Valhalla, New York · NCT04491370

• Evaluating progastrin levels in cancer patients

  This study is testing if measuring progastrin levels in the blood can help predict how cancer will progress and respond to treatment in patients with different types of cancer.

  Recruiting at 17 sites Hospices Civils de Lyon · Bron and 16 other locations · NCT03787056

NIH-funded research (33)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Immunotherapy for B-cell lymphoma using NK T cells

  A patient-focused immunotherapy approach using natural killer T cells engineered to target B-cell lymphoma, potentially offering off-the-shelf treatment options.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11418400

• Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma

  A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11403920

• Cardioprotective treatment choices for DLBCL patients at risk of heart damage

  Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.

  NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11402640

• Translating Genomics to Practice to Overcome Disparities in DLBCL

  A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11401446

• Spatially resolved single-cell biomarkers to guide B cell lymphoma therapy

  Aims to map tiny details in the tumor and immune cells of diffuse large B-cell lymphoma to help predict outcomes and guide treatments.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-11381871

• From pathogenesis to new targets for treating diffuse large B-cell lymphoma

  A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11377580

• Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma

  A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.

  NIH research University of Chicago · Chicago, United States · NIH-11353865

• Lowering c-Myc to treat aggressive large B‑cell lymphoma

  This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11321531

• EBV-related lymphoma in people with immune deficiency: understanding what drives the disease

  A doctor-scientist team will study a type of blood cancer linked to the Epstein-Barr virus in people with immune system problems to learn what makes it worse and how we can diagnose and treat it better.

  NIH research University of Vermont & St Agric College · Burlington, United States · NIH-11300775

• Computer models to improve combination treatments for diffuse large B‑cell lymphoma

  This project builds computer simulations to help design better combination drug regimens for people with diffuse large B‑cell lymphoma.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11260268

• Blocking EGR1 to treat aggressive diffuse large B‑cell lymphoma

  This project tests blocking a protein called EGR1 to help people with the aggressive ABC type of diffuse large B‑cell lymphoma who don't respond well to standard therapy.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11250037

• A new chemotherapy option for diffuse large B‑cell lymphoma

  This project develops a new chemotherapy drug intended to kill diffuse large B‑cell lymphoma cells, including cancers that don't respond to current treatment.

  NIH research Thomas Jefferson University · Philadelphia, United States · NIH-11229618

• EBV-positive diffuse large B-cell lymphoma in people with weakened immune systems

  Researchers will compare tumor and virus features in people with EBV-positive diffuse large B-cell lymphoma who have weakened immune systems from HIV or medical treatments to better link biology to health outcomes.

  NIH research University of Vermont & St Agric College · Burlington, United States · NIH-11222776

• Understanding how EBV affects lymphoma in patients with weakened immune systems

  This study is looking at how the Epstein-Barr virus affects a type of cancer called diffuse large B-cell lymphoma, especially in people with weakened immune systems, like those with HIV, to help find better ways to diagnose and treat this illness.

  NIH research University of Vermont & St Agric College · Burlington, United States · NIH-11222775

• NKT cell therapy for B‑cell lymphoma

  This project offers an off‑the‑shelf immune cell treatment using engineered natural killer T (NKT) cells for adults with B‑cell non‑Hodgkin lymphoma.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11178341

• Spatial immune cell maps for aggressive B‑cell lymphoma

  Researchers are using advanced single‑cell imaging to map cancer and immune cells in aggressive B‑cell lymphomas to find markers that could help guide treatment for adults.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-11160592

• New Ways to Treat Diffuse Large B Cell Lymphoma

  This project explores the genetic differences in diffuse large B cell lymphoma to discover new treatment options for patients.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11158782

• Understanding how genes affect immune responses in lymphoma treatment

  This study is looking at how the immune system interacts with diffuse large B cell lymphoma (DLBCL) to find out which genetic traits might help predict how well patients will respond to immunotherapy, so that treatments can be better tailored for those whose cancer has come back or hasn’t responded to other treatments.

  NIH research University of Chicago · Chicago, United States · NIH-11079518

• Understanding how specific mutations in EZH2 affect B-cell lymphoma

  This study is looking at how two different changes in the EZH2 gene affect B-cell lymphoma, using special mice to see how these changes influence the growth and survival of B-cells, which could help us understand how this type of cancer develops.

  NIH research Washington University · Saint Louis, United States · NIH-11067470

• Using blood tests to tailor treatment for lymphoma patients

  This study is looking at how a simple blood test can help doctors tailor treatment for people newly diagnosed with diffuse large B-cell lymphoma, so they can get the right amount of therapy to reduce side effects while still being effective.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11045782

• Targeting a protein involved in aggressive B-cell lymphoma

  This study is looking at a type of aggressive lymphoma called double and triple-hit lymphomas to understand how a protein named TBL1X affects the disease, with the goal of finding better treatments to help patients live longer and healthier lives.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11042777

• Developing computer models for combination therapy in aggressive lymphomas

  This study is looking at how different combinations of drugs can work together to treat Diffuse Large B-Cell Lymphoma (DLBCL) better, using computer simulations to understand how these treatments might affect different patients and their unique tumors.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11017031

• A new treatment for diffuse large B-cell lymphoma

  This study is testing a new treatment for diffuse large B-cell lymphoma (DLBCL) using a special compound that has shown promise in lab tests, and it's designed for patients who haven't had success with current therapies.

  NIH research Thomas Jefferson University · Philadelphia, United States · NIH-11001979

• Targeting genetic changes in aggressive lymphoma for better treatment

  This study is looking at how certain changes in genes on chromosome 18 can make diffuse large B-cell lymphoma (DLBCL) more aggressive, and it aims to create personalized treatments using new medicines that target these genetic markers to help improve outcomes for patients.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10986115

• Investigating EGR1 signaling pathways in aggressive lymphoma

  This study is looking at a tough type of lymphoma called ABC DLBCL to figure out why some treatments don’t work and hopes to find new ways to help patients who haven’t had success with current therapies.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-10982513

• Understanding how B-cell lymphoma evades the immune system

  This study is looking at how certain blood cancers called B-cell lymphomas hide from the immune system and how a molecule named FCRLA helps them do that, with the goal of finding new ways to boost the immune response and improve treatments for patients.

  NIH research Ralph H Johnson VA Medical Center · Charleston, United States · NIH-10951499

• Investigating new treatment targets for diffuse large B cell lymphoma

  This study is looking at a tough type of cancer called diffuse large B cell lymphoma (DLBCL) to find new ways to treat it by exploring the genes that might be causing the cancer to behave differently, and it’s for patients who are facing challenges with their current treatments.

  NIH research Columbia University Health Sciences · New York, United States · NIH-10928175

• Identifying important cell markers in B cell lymphoma

  This study is looking at a common type of lymphoma called Diffuse Large B-Cell Lymphoma (DLBCL) to find new ways to predict how well patients will respond to treatment by examining both cancer and non-cancer cells in the tumor, which could help create more personalized and effective therapies.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-10895500

• Understanding how BCL10 mutations affect treatment resistance in a type of lymphoma

  This study is looking at how certain changes in a gene called BCL10 might make it harder for people with diffuse large B cell lymphoma to respond to standard treatments, with the goal of finding better ways to help those patients.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-10894687

• Identifying biomarkers for HIV-related lymphoma in Malawi and South Africa

  This study is looking at how certain markers in tumors can help doctors better diagnose and treat HIV-related lymphoma in patients in Malawi and South Africa, aiming to improve care for those facing this challenge.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-10891547

• Understanding how MYC gene activation affects diffuse large B-cell lymphoma

  This study is looking at how a gene called MYC behaves in a type of cancer called diffuse large B-cell lymphoma (DLBCL) to find new ways to improve treatments and help doctors predict how the disease will progress for patients.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-10880680

• Understanding how the surrounding tissue affects B-cell lymphoma growth and immune response

  This study is looking at how certain cells and structures around lymphoma tumors help the cancer grow and avoid the immune system, with the goal of finding new ways to treat patients with diffuse large B-cell lymphoma.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-10746427

• Identifying genetic markers for better treatment of B-cell lymphoma

  This study is looking at how certain genes might help doctors understand how well patients with diffuse large B-cell lymphoma (DLBCL) will respond to common treatments, so they can improve care and outcomes for everyone affected by this type of cancer.

  NIH research Duke University · Durham, United States · NIH-10674524

Related topics

Quick answers

How many B-cell Lymphoma clinical trials are recruiting right now?

40, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in United States (19 trials), China (18 trials), Australia (5 trials), Canada (4 trials), Italy (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 12, Phase 1/2: 10, Phase 2: 9, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →